// App-Quantinova.ai

P4-22-03 : Palbociclib in combination with endocrine therapy in treatment-naive and previously treated elderly women with HR+, HER2 advanced breast cancer: a pooled analysis from randomized phase 2 and 3 studies

Researchers

Presenter

  • HS Rugo

Principal Investigators

  • NC Turner

  • RS Finn

  • AA Joy

  • S Verma

  • N Harbeck

  • S Moulder

  • N Masuda

  • Y-H Im

  • K Zhang

  • S Kim

  • W Sun

  • P Schnell

  • C Huang-Bartlett

  • D Slamon

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • The Institute of Cancer Research & The Royal Marsden, London, Spain

  • University of Calgary, Calgary, AB, Canada

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

  • Brustzentrum der Universitat Munchen (LMU), Munich, Germany

  • National Hospital Organization Toneyama National Hospital, Toyonaka, Japan

  • UCLA David Geffen School of Medicine, Los Angeles, CA

Locations

  • Canada

  • Japan

  • Germany

  • United Kingdom

  • United States

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Neutropenia

  • Solid malignancies

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Fulvestrant

  • Palbociclib

  • Letrozole

Outcome

  • N/A

Study Design

  • randomized

  • double blind/blinded

  • pharmacokinetics

Phase

  • II

Study Id's

  • NCT00141297

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved